Results 71 to 80 of about 4,764 (176)

Correlation of the decrease in exercise tolerance with the ventilation and gas exchange disturbances in patients with various phenotypes of chronic heart failure

Клинический разбор в общей медицине
Aim. To assess parameters of ventilation and gas exchange and determine the factors associated with the peak oxygen consumption levels in patients with various phenotypes of chronic heart failure (CHF). Methods. The study was focused on further analysis
Yulia L. Begrambekova, Nino A. Karanadze, Artem N. Zadoia, Elena M. Seredenina, Alina G. Plisyuk   +4 more
doaj   +1 more source

Diabetic Retinopathy Severity and Heart Failure Outcomes in Type 2 Diabetes Mellitus

Journal of Diabetes, Volume 18, Issue 7, July 2026.
In type 2 diabetes, worsening diabetic retinopathy is associated with both systolic and diastolic dysfunction and independently predicts incident heart failure. Routine retinal evaluation may help identify patients at increased microvascular and cardiovascular risk.
Feng‐Ching Shen, Pei‐Kang Liu, Yi‐Chen Huang, Teng‐Hui Huang, Ming‐Yen Lin, Yi‐Hsueh Liu, Tien‐Chi Huang, Mei‐Chuan Kuo, Yi‐Wen Chiu, Shang‐Jyh Hwang, Yi‐Ting Lin, Ping‐Hsun Wu   +11 more
wiley   +1 more source

Effects of soluble guanylyl cyclase stimulation on muscle oxygenation and exercise capacity in heart failure with mildly reduced ejection fraction

Experimental Physiology
Heart failure (HF) with a mildly reduced ejection fraction (HFmrEF; 40%–49%) is present in ≤25% of HF patients. Therapeutic treatment options for HFmrEF‐associated exercise intolerance are limited.
Ramona E. Weber, Kiana M. Schulze, Andrew G. Horn, Tyler E. McCoach, Zachary J. White, K. Sue Hageman, Stephanie E. Hall, Peter Sandner, Brad J. Behnke, Timothy I. Musch, David C. Poole   +10 more
doaj   +1 more source

Association between serum matrix metalloproteinase-12/angiotensin II profile and left ventricular hypertrophy in patients with heart failure

Archives of the Balkan Medical Union, 2020
Introduction. Matrix metalloproteinases (MMPs) are important target genes for angiotensin II (AII), which subsequently alters MMP expression in extracellular matrix (ECM) and lead to remodeling process. Objective. To investigate whether an association
Asparuh G. NIKOLOV, Maria L. TZEKOVA, Konstantin M. KOSTOV, Alexander B. BLAZHEV   +3 more
doaj   +1 more source

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction

Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2018
Objective: To assess the effects of comorbidities, fragility, and quality of life (QOL) on long-term prognosis in ambulatory patients with heart failure (HF) with midrange left ventricular ejection fraction (HFmrEF), an unexplored area.
Paloma Gastelurrutia, PhD, Josep Lupón, MD, PhD, Pedro Moliner, MD, Xiaobo Yang, MB, German Cediel, MD, PhD, Marta de Antonio, MD, PhD, Mar Domingo, MD, PhD, Salvador Altimir, MD, Beatriz González, CN, Margarita Rodríguez, CN, Carmen Rivas, CN, Violeta Díaz, CN, Erik Fung, MB, ChB, PhD, Elisabet Zamora, MD, PhD, Javier Santesmases, MD, Julio Núñez, MD, PhD, Jean Woo, MD, Antoni Bayes-Genis, MD, PhD, FESC   +17 more
doaj   +1 more source

Finerenone: A breakthrough drug for patients of HFmrEF and HFpEF

Journal of the Pakistan Medical Association
Madam, Heart failure (HF) is one of the major cardiovascular diseases, affecting more than 64 million people worldwide.1 HFmrEF and HFpEF are subtypes of HF characterised by LVEFs of 41-49% and >50%, respectively.1 ARBs, ACE inhibitors, aldosterone antagonists and loop diuretics are some of the drug classes that have been used in the management of ...
openaire   +2 more sources

Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF

JACC: Heart Failure
في حين أنه لا يوصى باستخدام حاصرات بيتا لعلاج HFpEF وفقًا لأحدث إرشادات ESC و AHA/ACC/HFSA، إلا أن هذه العلاجات لا تزال شائعة الاستخدام لإدارة الاعتلال المشترك. كان هناك قلق من أن حاصرات بيتا قد تؤثر سلبًا على النتائج السريرية من خلال الحد من الاستجابة الكرونوتروبية في HFpEF.
Alexander Peikert, Bradley A. Bart, Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Mikhail Kosiborod, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Silvio E. Inzucchi, Felipe A. Martínez, Rudolf A. de Boer, Adrian F. Hernandez, Sanjiv J. Shah, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon, Orly Vardeny   +18 more
openaire   +1 more source

Obesity Paradox in Heart Failure with Mildly Reduced Ejection Fraction

Pragmatic and Observational Research
Marielen Reinhardt,1,* Tobias Schupp,1,* Mohammad Abumayyaleh,1 Felix Lau,1,2 Alexander Schmitt,1 Noah Abel,1 Muharrem Akin,2 Jonas Rusnak,3 Ibrahim Akin,1 Michael Behnes1 1Department of Cardiology, Angiology, Haemostaseology and Medical ...
Reinhardt M, Schupp T, Abumayyaleh M, Lau F, Schmitt A, Abel N, Akin M, Rusnak J, Akin I, Behnes M   +9 more
doaj  

Outcomes of KDIGO-Defined CKD in U.S. Veterans With HFpEF, HFmrEF, and HFrEF

JACC: Heart Failure
Chronic kidney disease (CKD) is defined by the KDIGO (Kidney Disease: Improving Global Outcomes) guideline as abnormal kidney structure or function, present for >3 months, with implications for health. KDIGO-defined CKD is associated with poor outcomes in patients with heart failure (HF).
Samir Patel, Venkatesh K. Raman, Charles Faselis, Gregg C. Fonarow, Phillip H. Lam, Amiya A. Ahmed, Paul A. Heidenreich, Stefan D. Anker, Prakash Deedwania, Charity J. Morgan, Sijian Zhang, Hans Moore, Janani Rangaswami, George Bakris, Javed Butler, Helen M. Sheriff, Richard M. Allman, Qing Zeng-Treitler, Wen-Chih Wu, Ali Ahmed   +19 more
openaire   +3 more sources

Aldosterone Synthase Inhibition in Diabetes and Cardiorenal Metabolic Disease

Journal of Diabetes, Volume 18, Issue 7, July 2026.
Zachary Bloomgarden
wiley   +1 more source